Sponsor

Chiesi Farmaceutici S.p.A.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Chiesi Farmaceutici S.p.A. appears in 142 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials142
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])NCT07666490 · lead sponsor · 2026-06-28
RECRUITING
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsNCT07546981 · lead sponsor · 2026-06-26
RECRUITING
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate AsthmaNCT07301736 · lead sponsor · 2025-12-17
RECRUITING
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)NCT05652439 · lead sponsor · 2022-12-02
RECRUITING
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaNCT07858123 · lead sponsor · 2026-11-16
NOT_YET_RECRUITING
Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With AsthmaNCT07851623 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001NCT06900816 · lead sponsor · 2025-03-28
COMPLETED
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) StudyNCT06892756 · lead sponsor · 2025-03-18
COMPLETED
Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)NCT06480890 · lead sponsor · 2024-07-02
COMPLETED
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy VolunteersNCT06395610 · lead sponsor · 2024-03-28
COMPLETED
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).NCT06264674 · lead sponsor · 2023-11-27
COMPLETED
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance TherapyNCT06029595 · lead sponsor · 2023-11-26
TERMINATED
Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®NCT05898984 · lead sponsor · 2023-04-24
COMPLETED
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)NCT05830071 · lead sponsor · 2023-03-29
COMPLETED
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled CorticosteroidNCT05292586 · lead sponsor · 2022-08-31
COMPLETED
A Study to Compare the Effects of Two Propellants in Adults With Mild AsthmaNCT05472662 · lead sponsor · 2022-08-03
COMPLETED
PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy VolunteersNCT05431426 · lead sponsor · 2022-07-29
COMPLETED
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control SubjectsNCT05373953 · lead sponsor · 2022-05-05
COMPLETED
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDNCT04320342 · lead sponsor · 2022-04-27
COMPLETED
Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABANCT05018598 · lead sponsor · 2022-02-25
TERMINATED
Study in Adult Patients With Moderate to Severe AsthmaNCT04886999 · lead sponsor · 2022-02-24
COMPLETED
CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPDNCT05097014 · lead sponsor · 2021-10-28
COMPLETED
TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPDNCT04671355 · lead sponsor · 2021-10-04
WITHDRAWN
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · lead sponsor · 2021-07-14
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · lead sponsor · 2021-07-12
TERMINATED
Functional Respiratory Imaging Study (DARWiIN)NCT04876677 · lead sponsor · 2021-05-18
COMPLETED
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy SubjectsNCT04756960 · lead sponsor · 2021-03-10
COMPLETED
Study on Patterns of Care in Mild Asthmatic PatientsNCT04598555 · lead sponsor · 2021-02-25
COMPLETED
Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)NCT04739774 · lead sponsor · 2021-02-22
COMPLETED
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic AsthmaNCT04049175 · lead sponsor · 2019-08-28
TERMINATED
Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's AdherenceNCT03951714 · lead sponsor · 2019-08-12
COMPLETED
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD SubjectsNCT04032535 · lead sponsor · 2019-07-24
COMPLETED
PK Linearity and Steady State PK of CHF 6532 in Healthy SubjectsNCT03942666 · lead sponsor · 2019-05-10
COMPLETED
PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. CaucasiansNCT03859414 · lead sponsor · 2019-03-18
COMPLETED
Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD PatientsNCT03795350 · lead sponsor · 2019-01-14
TERMINATED
CHF6467 SAD and MAD in Patients With Diabetic Foot UlcerNCT04077671 · lead sponsor · 2018-10-17
COMPLETED
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)NCT03888131 · lead sponsor · 2018-07-30
COMPLETED
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)NCT03590379 · lead sponsor · 2018-06-15
COMPLETED
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366NCT03378648 · lead sponsor · 2017-12-28
COMPLETED
Functional Respiratory Imaging Study (FRI)NCT03268226 · lead sponsor · 2017-11-20
COMPLETED
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.NCT03453112 · lead sponsor · 2017-10-09
COMPLETED
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)NCT03086460 · lead sponsor · 2017-09-08
COMPLETED
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic SubjectsNCT03084718 · lead sponsor · 2017-07-28
COMPLETED
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary DiseaseNCT03084796 · lead sponsor · 2017-07-28
COMPLETED
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.NCT03108534 · lead sponsor · 2017-02-28
COMPLETED
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPDNCT02986321 · lead sponsor · 2016-12-15
COMPLETED
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)NCT03197818 · lead sponsor · 2016-12-14
COMPLETED
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD PatientsNCT02975843 · lead sponsor · 2016-11-21
COMPLETED
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPDNCT03004417 · lead sponsor · 2016-10-31
COMPLETED
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaNCT02560610 · lead sponsor · 2016-09-01
COMPLETED
Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years OldNCT02787967 · lead sponsor · 2016-08-01
COMPLETED
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)NCT02676089 · lead sponsor · 2016-04-06
COMPLETED
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy VolunteersNCT02743013 · lead sponsor · 2016-04-01
COMPLETED
Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPDNCT02680197 · lead sponsor · 2016-02-29
COMPLETED
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABANCT02676076 · lead sponsor · 2016-02-17
COMPLETED
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPDNCT02815488 · lead sponsor · 2016-01-22
TERMINATED
Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001NCT03004495 · lead sponsor · 2016-01-01
COMPLETED
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD PatientsNCT02579850 · lead sponsor · 2015-05-29
COMPLETED
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)NCT02467452 · lead sponsor · 2015-05-01
COMPLETED
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy VolunteersNCT02359292 · lead sponsor · 2015-02-01
COMPLETED

Drugs studied in this sponsor's trials

17 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Chiesi Farmaceutici S.p.A. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo23
formoterol4
albuterol3
beclomethasone dipropionate3
glycopyrrolate3
salmeterol3
formoterol fumarate2
roflumilast2
placebo RxCUI 8375 · Lead sponsor in 22 linked trial(s) · 0 currently recruiting 23 trials formoterol RxCUI 25255 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials albuterol RxCUI 435 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials beclomethasone dipropionate RxCUI 1348 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials glycopyrrolate RxCUI 4955 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials salmeterol RxCUI 36117 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials formoterol fumarate RxCUI 236216 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials roflumilast RxCUI 1091836 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials tiotropium RxCUI 69120 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials amlodipine 10 MG RxCUI 329526 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial beclomethasone RxCUI 1347 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial budesonide RxCUI 19831 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cyclosporine RxCUI 3008 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial erythromycin RxCUI 4053 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial formoterol Inhalation Solution RxCUI 2108395 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial itraconazole RxCUI 28031 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial moxifloxacin RxCUI 139462 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor127
collaborator15
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.